1-4 of 4
annamycin
Close
Sort by
Journal Articles

Clinical Efficacy of L-Annamycin, a Liposomal Formulated Non-Cross-Resistant and Non-Cardiotoxic Anthracycline in Relapsed/Refractory AML Patients

Lidia Gil, MD PhD, Robert C. Shepard, MD, Sandra L Silberman, MD PhD, Ewa Maria Zak, MSc, Waldemar Priebe, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5147.
https://doi.org/10.1182/blood-2019-129268
Published: 2019
Journal Articles

Biodistribution and Efficacy of L-Annamycin in a Novel Imageable AML Mouse Model

Rafal Zielinski, PhD, Krzysztof Grela, PhD, Stanislaw Skora, PhD, Rodrigo Jacamo, PhD, Izabela Fokt, PhD, Matthew Sander, Magdalena Remiszewski, PhD, Edward Felix, PhD, Meenakshi Shanmugasundaram, Malgorzata Anna Zal, MSc, Michael Andreeff, MD PhD, Waldemar Priebe, PhD, Tomasz Zal, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5150.
https://doi.org/10.1182/blood-2019-131977
Published: 2019
Journal Articles

Phase I Trial of Nanomolecular Liposomal Annamycin in Adult Patients with Refractory Acute Lymphoblastic Leukemia.

Meir Wetzler, MD, Eunice S. Wang, MD, Robert Shepard, MD, FACP, Deborah A. Thomas, MD, Michael Andreeff, Susan O'Brien, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2009) 114 (22): 4098.
https://doi.org/10.1182/blood.V114.22.4098.4098
Published: 2009
Journal Articles

The novel anthracycline annamycin is not affected by P-glycoprotein- related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines

U Consoli, W Priebe, YH Ling, R Mahadevia, M Griffin, S Zhao, R Perez-Soler, M Andreeff
Journal: Blood
Blood (1996) 88 (2): 633–644.
https://doi.org/10.1182/blood.V88.2.633.bloodjournal882633
Published: 1996